Clinical Trial

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2024-07-25; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2024-08-09
Trial Details
NCT Number NCT06528691
Lead Sponsor St. Jude Children's Research Hospital
Collaborators: Hoffmann-La Roche
Conditions High Grade Glioma, CNS Tumor
Enrollment 52 participants
Start Date 2026-05-01
Primary Completion 2027-11 (estimated)
Study Completion 2032-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-13